Biogen (NASDAQ: BIIB) and Alimera Sciences (NASDAQ:ALIM) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and earnings.

Insider & Institutional Ownership

87.7% of Biogen shares are held by institutional investors. Comparatively, 37.2% of Alimera Sciences shares are held by institutional investors. 0.3% of Biogen shares are held by company insiders. Comparatively, 14.7% of Alimera Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

Biogen has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Comparatively, Alimera Sciences has a beta of 2.2, indicating that its share price is 120% more volatile than the S&P 500.

Valuation & Earnings

This table compares Biogen and Alimera Sciences’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Biogen $11.72 billion 5.90 $6.42 billion $15.23 21.46
Alimera Sciences $35.96 million 2.63 -$16.78 million ($0.39) -3.51

Biogen has higher revenue and earnings than Alimera Sciences. Alimera Sciences is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Biogen and Alimera Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Biogen 28.10% 37.42% 20.12%
Alimera Sciences -68.58% N/A -36.39%

Analyst Ratings

This is a breakdown of current ratings and target prices for Biogen and Alimera Sciences, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biogen 0 11 12 1 2.58
Alimera Sciences 0 0 3 0 3.00

Biogen currently has a consensus target price of $332.00, suggesting a potential upside of 1.60%. Alimera Sciences has a consensus target price of $4.00, suggesting a potential upside of 191.97%. Given Alimera Sciences’ stronger consensus rating and higher probable upside, analysts plainly believe Alimera Sciences is more favorable than Biogen.

Summary

Biogen beats Alimera Sciences on 10 of the 14 factors compared between the two stocks.

Biogen Company Profile

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company’s product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.

Alimera Sciences Company Profile

Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Company’s product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.

Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.